--- title: "12 Health Care Stocks Moving In Friday's Pre-Market Session" description: "Gainers in Friday's pre-market session include PaxMedica, Allarity Therapeutics, HCW Biologics, Portage Biotech, PepGen, and Akanda. Losers include Motus GI Hldgs, Adial Pharmaceuticals, Monogram Orth" type: "news" locale: "en" url: "https://longbridge.com/en/news/201829825.md" published_at: "2024-04-12T12:09:54.000Z" --- # 12 Health Care Stocks Moving In Friday's Pre-Market Session > Gainers in Friday's pre-market session include PaxMedica, Allarity Therapeutics, HCW Biologics, Portage Biotech, PepGen, and Akanda. Losers include Motus GI Hldgs, Adial Pharmaceuticals, Monogram Orthopaedics, Eliem Therapeutics, Akili, and Nkarta. ### Gainers - **PaxMedica** (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. - **Allarity Therapeutics** (NASDAQ:ALLR) stock increased by 55.84% to $3.58. The company's market cap stands at $1.6 million. - **HCW Biologics** (NASDAQ:HCWB) shares increased by 20.77% to $1.86. The market value of their outstanding shares is at $70.3 million. - **Portage Biotech** (NASDAQ:PRTG) stock rose 17.6% to $0.59. The company's market cap stands at $11.6 million. - **PepGen** (NASDAQ:PEPG) shares rose 16.75% to $14.84. The company's market cap stands at $480.1 million. - **Akanda** (NASDAQ:AKAN) stock increased by 15.82% to $0.17. The company's market cap stands at $2.0 million. ### Losers - **Motus GI Hldgs** (NASDAQ:MOTS) stock fell 26.1% to $0.31 during Friday's pre-market session. The company's market cap stands at $1.6 million. - **Adial Pharmaceuticals** (NASDAQ:ADIL) shares decreased by 12.42% to $2.61. The market value of their outstanding shares is at $10.5 million. - **Monogram Orthopaedics** (NASDAQ:MGRM) shares decreased by 11.8% to $3.59. The company's market cap stands at $113.5 million. - **Eliem Therapeutics** (NASDAQ:ELYM) stock declined by 8.74% to $4.18. The company's market cap stands at $115.8 million. - **Akili** (NASDAQ:AKLI) stock declined by 8.64% to $0.23. The market value of their outstanding shares is at $18.4 million. - **Nkarta** (NASDAQ:NKTX) stock decreased by 7.78% to $8.12. The company's market cap stands at $571.5 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/ This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [ALLR.US - Allarity Therapeutics](https://longbridge.com/en/quote/ALLR.US.md) - [PXMD.US - PaxMedica](https://longbridge.com/en/quote/PXMD.US.md) - [PEPG.US - PepGen](https://longbridge.com/en/quote/PEPG.US.md) - [AKAN.US - Akanda](https://longbridge.com/en/quote/AKAN.US.md) - [CLYM.US - Climb Bio](https://longbridge.com/en/quote/CLYM.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Climb Bio 在峰会上透露，计划在 2026 年发布 5 项数据，并重点介绍其 CD19 和 APRIL“清扫者” 项目 | Climb Bio（纳斯达克代码：CLYM）在古根海姆新兴前景生物技术峰会上宣布了 2026 年即将发布的五项临床数据。该公司专注于自身免疫疾病，拥有两个抗体项目：一种针对 CD19 的单克隆抗体和一种针对 IgA 肾病的 APRIL 单抗 | [Link](https://longbridge.com/en/news/275867297.md) | | PaxMedica｜10-Q：2024 财年 Q3 营收 0 美元 | | [Link](https://longbridge.com/en/news/272604818.md) | | PepGen Inc 预计每股将亏损 35 美分 - 财报预览 | PepGen Inc 预计在截至 2025 年 12 月 31 日的季度报告中每股亏损 35 美分，季度收入没有变化。平均分析师评级为 “买入”，12 个月的中位数目标价为 9.50 美元，比最后收盘价 6.66 美元上涨 42.6%。之前 | [Link](https://longbridge.com/en/news/276449604.md) | | Allarity Therapeutics 与美国退伍军人事务部合作开展二期癌症试验 | Allarity Therapeutics Inc. 已与美国退伍军人事务部合作，开展针对复发性小细胞肺癌的第二阶段临床试验，评估 stenoparib 和 temozolomide 的联合使用。该试验由退伍军人事务部的精准肿瘤学特别关注小 | [Link](https://longbridge.com/en/news/274659689.md) | | Akanda 完成 700 万美元的可转换票据发行 | Akanda Corporation 已完成与机构投资者的 700 万美元 12 个月可转换票据的私募配售。所得款项将用于市场营销（230 万美元）、营运资金和一般企业用途（260 万美元）以及债务偿还（210 万美元）。Univest S | [Link](https://longbridge.com/en/news/273667042.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.